Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 4Phase 2/3 1

Status

Completed 6

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Genitourinary 2Thoracic 1Other neoplasm 1Head & Neck 1Breast 1

Conditions

Neoplasms 3Urinary Bladder Neoplasms 2Neoplasm Metastasis 2Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1Breast Cancer Metastatic 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Rogaratinib × Clear all
NCT03473756 2025-04-09

FORT-2

Bayer

Phase 1 Completed
37 enrolled 15 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04483505 2023-12-28

ROGABREAST

Fundacion CRIS de Investigación para Vencer el Cáncer

Phase 1 Completed
9 enrolled
BreastOther neoplasm

Breast Cancer Metastatic

NCT03517956 2022-07-14

ROCOCO

Bayer

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03788603 2021-03-29

Rogaratinib (BAY1163877) in Chinese Patients

Bayer

Phase 1 Completed
1 enrolled
Tumor-Agnostic

Neoplasms

NCT02592785 2018-04-18

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Bayer

Phase 1 Completed
9 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡